Last reviewed · How we verify
NCT07241689
Effects of Protein Supplementation on 4 Weeks of Alternate-day Fasting on Fasting Blood Glucose, Resting Blood Pressure, and Body Composition in Young Men
NA trial testing protein supplement in Obesity & Overweight in 26 participants. Completed in 23 March 2018.
23 March 2018
Quick facts
| Lead sponsor | Nanyang Technological University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 26 |
| Start date | 17 January 2018 |
| Primary completion | 23 March 2018 |
| Estimated completion | 23 March 2018 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- protein supplement — full drug profile →
- No supplementation — full drug profile →
Conditions studied
- Obesity & Overweight — all drugs for Obesity & Overweight →
Sponsor
Nanyang Technological University
Who can join
Adults 21 to 35, male only, with Obesity & Overweight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this study are to examine the effects of protein supplementation on 4 weeks of alternate-day fasting (ADF) on fasting blood glucose, resting blood pressure, and body composition in young Asian men with unhealthy body mass index ≥ 23 kg/m2. To achieve the objective, 40 young men aged 21 to 35 years old will be recruited to participate in this study and complete a 4-week ADF programme. The fasting programme starts at 12 midnight and alternates between fasting and feeding days. Each fasting or feeding day is 24-hour in duration. On fasting days, no food and beverages are allowed except for ad libitum intake of plain water and/or other zero-calorie beverages, and a small meal between 400-600 kcal. In this study, participants would be randomly assigned to either the control or protein supplementation group (20 in each group). The control group will consume a small meal of their choice as long as it is between 400-600 kcal while the protein supplementation group will consume a small meal between 400-600 kcal that will include a protein supplement that would be provided (125 kcal, 25 g protein) and with the remainder of the meal of their choice. For both groups in this study, the small meal is to be consumed during 12 pm to 2 pm for standardisation to ensure consistency in total duration of fasting and feeding. The programme will end after 4 weeks (28 days) of continuous alternate-day fasting. Fasting blood glucose, resting blood pressure and heart rate, body mass, height, and body composition will be measured before and after 4-week of ADF. In addition, these measurements, except body composition, will be repeated at the end of each week of ADF. The research hypothesis are: 1) 4 weeks of ADF will reduce body mass via both fat and muscle loss, and improve health indices as measured by fasting blood glucose and resting blood pressure in young individuals with BMI greater than the desired healthy range, and 2) protein supplementation during fasting days will reduce muscle loss during loss of body mass.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of Four Weeks of Alternate-Day Fasting with or Without Protein Supplementation-A Randomized Controlled Trial.
Pang BWJ, Yang Y, Rashiqah N, Huang CB, et al · · 2025 · PMID 41373982 · DOI 10.3390/nu17233691
Verify or expand the search:
- PubMed search for NCT07241689
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of protein supplement
Trials testing the same drug.
- NCT07271043 — Nutrition+: Effect of a High-Protein Diabetes Formula on Body Composition in Type 2 Diabetes Patients Treated With Incre · NA · recruiting
- NCT04564391 — Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins · NA · unknown
- NCT04091841 — Trial of Protein Supplement on Vertebral Fusion in Posterior Spine Fusion Surgery · NA · completed
- NCT04170036 — Do High Doses of Protein Supplements Affect Serum Lipid Profiles? · completed
Other recruiting trials for Obesity & Overweight
Currently open trials in the same condition.
- NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
- NCT07457437 — Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment · NA · recruiting
- NCT07396805 — Trial of Food Is Medicine Approaches for Obesity Treatment in Adults With Food Insecurity · NA · recruiting
- NCT07349381 — A Food-Effect Study of CX11 in Healthy Participants · Phase 1 · recruiting
- NCT07187830 — Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD · recruiting
Other Nanyang Technological University trials
Trials by the same sponsor.
- NCT07425951 — Building Cognitive Behavioural Skills With StoryBooks to Reduce Emotional Difficulties in Kindergarten Years · NA · recruiting
- NCT07497711 — Virtual Menstrual Pain Approaches in Females · Phase 2, PHASE3 · not yet recruiting
- NCT07288892 — Effects of Pulsed Electromagnetic Field Therapy on Sport Performance and Recovery · NA · recruiting
- NCT06991764 — Investigating the Effectiveness of a 2-week Novel Non-invasive Brain Stimulation Technique on Cognitive Outcomes in Heal · NA · not yet recruiting
- NCT06732297 — Stronger Families Through Art Therapy: A Mixed Methods Programme Evaluation Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07241689 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanyang Technological University
- Last refreshed: 21 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07241689.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing